Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
July 2, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 2, 2007
- TOPICS 3 articles
July 2, 2007
- BVs Need Efficient Reorganization: Mr Iwatani of Kringle Pharma
July 2, 2007
- Banyu to Boost Promotion of Once-Weekly Fosamac
July 2, 2007
- Astellas Launches Advagraf in the UK, Germany
July 2, 2007
- Takeda to Consolidate Its Top Position with Once-Weekly Risedronate Formulation
July 2, 2007
- Eisai Launches Inovelon in Europe
July 2, 2007
- NEW PRODUCTS／Otsuka: Pletaal Powder 20% That Can Be Taken without Water
July 2, 2007
- Toyama Licenses T-5224 to Roche
July 2, 2007
- BUSINESS NEWS IN BRIEF
July 2, 2007
- Teijin to Boost Market Share in the Field of Bone Treatment
July 2, 2007
- FPMAJ Subcommittees Present Reports on Drug Pricing Reform
July 2, 2007
- Clinical, Commercialization Research to Receive Priority in FY2008 Budgeting: Mr Araki
July 2, 2007
- Chugai to Conduct Studies to Clarify Causal Relationship between Tamiflu and Abnormal Behavior
July 2, 2007
- REGULATORY NEWS IN BRIEF
July 2, 2007
- JGPMA Presents Its Proposal to the FPMAJ
July 2, 2007
- Physicians Need Reliable Brands: FPMAJ Survey
July 2, 2007
- GENERICS NEWS IN BRIEF
July 2, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…